Biogen is buying Alcyone Therapeutics after working with the company for more than two years on a better delivery system for neurological medicines built around antisense oligonucleotides.

Biogen在与Alcyone Therapeutics合作两年多后，收购了这家公司，二者共同研发围绕反义寡核苷酸构建的神经科药物的更佳递送系统。

Under terms

条款之下

, Biogen will spend $85 million upfront to acquire the privately held company and promise additional payments to Alcyone investors if certain development and regulatory goals are reached. Biogen will gain all rights to ThecaFlex DRx, an implantable subcutaneous port and catheter device it’s been developing with Alcyone since .

Biogen将花费8500万美元预付款收购这家私人公司，并承诺如果达到某些开发和监管目标，将向Alcyone的投资者提供额外付款。Biogen将获得ThecaFlex DRx的全部权利，这是一种可植入的皮下端口和导管装置，自与Alcyone合作以来一直在开发中。

The companies have two studies underway testing the system’s delivery of Biogen’s Spinraza drug for spinal muscular atrophy, Biogen said. Lowell, Massachusetts-based Alcyone has been developing ThecaFlex DRx since 2019 and manufactures the product locally.

Biogen表示，两家公司正在进行两项研究，测试该系统递送Biogen用于脊髓性肌萎缩症的药物Spinraza的效果。位于马萨诸塞州洛厄尔的Alcyone自2019年以来一直在开发ThecaFlex DRx，并在本地生产该产品。

Ionis Pharmaceuticals

艾奥尼斯制药公司

, Biogen has a long history with antisense oligonucleotides, which can modify the production of proteins in the body. The two companies developed the blockbuster drug Spinraza, which works by steadily increasing the amount of a key motor neuron protein in the central nervous system.

Biogen在反义寡核苷酸领域有着悠久的历史，这类化合物可以调节人体内蛋白质的生成。两家公司共同开发了重磅药物Spinraza，该药物通过稳步增加中枢神经系统中一种关键运动神经元蛋白的含量来发挥作用。

Spinraza has found great success, bringing in almost

Spinraza取得了巨大的成功，带来了几乎

$1.6 billion in revenue

16亿美元的收入

last year, but it must be administered directly into the central nervous system, requiring repeat lumbar punctures. The idea behind ThecaFlex DRx is to offer patients an easier experience, with an implanted device that enables routine administration of medicines like Spinraza.

去年，但必须直接注入中枢神经系统，需要重复腰椎穿刺。ThecaFlex DRx 背后的理念是为患者提供更便捷的体验，通过植入设备实现像 Spinraza 这样的药物的常规给药。

Successful testing could open up many more possibilities for the administration of neurological medicines like Spinraza. The current tests will “inform pathways” for Biogen’s broader portfolio, the company said.

成功的测试可以为Spinraza等神经科药物的施用开辟更多可能性。公司表示，当前的测试将“为Biogen更广泛的产品组合提供途径”。

In addition to Spinraza, Biogen and

除了Spinraza，Biogen和

Ionis

离子

have successfully brought

已经成功带来了

Qalsody

托夫森特岊

to market for ALS and are working on other treatments for Alzheimer’s disease and spinal muscular atrophy. They have also had some stumbles along the way,

推向市场用于治疗ALS，并正在研究其他针对阿尔茨海默病和脊髓性肌萎缩症的治疗方法。在此过程中，他们也遇到了一些挫折，